We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Renalytix Plc | LSE:RENX | London | Ordinary Share | GB00BYWL4Y04 | ORD 0.25P |
| Price Change | % Change | Share Price | Shares Traded | Last Trade
|
|
|---|---|---|---|---|---|
| 0.00 | 0.00% | 9.50 | 31,360 | 07:31:34 |
| Bid Price | Offer Price | High Price | Low Price | Open Price | |
|---|---|---|---|---|---|
| 9.00 | 10.00 | 9.50 | 9.50 | 9.50 | |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Services, Nec | USD 2.29M | USD -45.47M | USD -0.1373 | -0.69 | 31.46M |
| Last Trade Time | Trade Type | Trade Size | Trade Price | Currency |
|---|---|---|---|---|
| 08:16:42 | O | 220,000 | 9.10 | GBX |
| Date | Time | Source | Headline |
|---|---|---|---|
| 11/12/2024 | 11:46 | UK RNS | Renalytix PLC Director/PDMR dealings |
| 09/12/2024 | 17:27 | UK RNS | Renalytix PLC Director/PDMR share purchase |
| 06/12/2024 | 07:00 | UK RNS | Renalytix PLC Director/PDMR share purchase |
| 04/12/2024 | 12:35 | UK RNS | Renalytix PLC Director/PDMR share purchase |
| 02/12/2024 | 07:00 | UK RNS | Renalytix PLC Directorate Change |
| 26/11/2024 | 14:06 | UK RNS | Renalytix PLC Holding(s) in Company |
| 26/11/2024 | 07:00 | UK RNS | Renalytix PLC Publication of Annual Report and Notice of AGM |
| 25/11/2024 | 18:23 | UK RNS | Renalytix PLC Holding(s) in Company |
| 21/11/2024 | 07:00 | UK RNS | Renalytix PLC Audited Full Year Fiscal 2024 Results |
| 20/11/2024 | 07:00 | UK RNS | Renalytix PLC Financial Results for Q1 of Fiscal Year 2025 |
Renalytix (RENX) Share Charts1 Year Renalytix Chart |
|
1 Month Renalytix Chart |
Intraday Renalytix Chart |
| Date | Time | Title | Posts |
|---|---|---|---|
| 11/12/2024 | 20:59 | Renalytix - AI Solutions Transforming The Management Of Kidney Disease | 2,604 |
| 14/12/2020 | 14:12 | RenalytixAI : AI solutions for Kidney disease detection, care and drug discovery | 265 |
| Trade Time | Trade Price | Trade Size | Trade Value | Trade Type |
|---|---|---|---|---|
| 08:17:21 | 9.10 | 220,000 | 20,020.00 | O |
| 08:17:20 | 9.10 | 220,000 | 20,020.00 | O |
| 08:17:17 | 9.30 | 150,000 | 13,950.00 | O |
| 08:17:13 | 9.30 | 150,000 | 13,950.00 | O |
| 08:16:43 | 9.14 | 31,360 | 2,864.89 | O |
| Top Posts |
|---|
Posted at 13/12/2024 08:20 by Renalytix Daily Update Renalytix Plc is listed in the Services, Nec sector of the London Stock Exchange with ticker RENX. The last closing price for Renalytix was 9.50p.Renalytix currently has 331,206,012 shares in issue. The market capitalisation of Renalytix is £31,464,571. Renalytix has a price to earnings ratio (PE ratio) of -0.69. This morning RENX shares opened at 9.50p |
Posted at 10/12/2024 14:32 by earwacks The JB effect! Should have bought more I suppose but the risk was looking ominous. I got no reply to my question about conflicting RNS and whether they do or do not need future funding. I guess they don’t actually know for sure. Seems like not in the next 12 months and by then they could be flying . Lot of uncertainties in USA , but if they want a healthier fitter society then Renx can help with that and reduce their costs. Same applies to Vrci. |
Posted at 28/11/2024 07:44 by collywobbler Can’t argue with any of that but here’s the main issue . Aim and the uk are in the poop. No traders no interest in any share . Aim only ever worked on hype and there’s no hype so unfortunately no hope |
Posted at 11/7/2024 12:25 by thiopia UK lagging US priceUS price RNLX at $0.60 is equivalent to around 23-24p here US price RNLX at $0.50 is equivalent to around 19-20p here |
Posted at 14/5/2024 16:17 by faz Mills sold 2.5m shares for £500k, When they were £11 a share that was worth £27m. Nice going. Remind me to listen to Chris Mills next time he spouts on about investments. |
Posted at 11/4/2024 16:30 by 1jat The company has not given any thoughts on margins, but I would compare it with Pharma where product cost is typically 20% and sales/general costs another 30% for an established product….There would be costs anyway in operating the test, so the incremental costs of outsourcing might push the lab cost up by a further 10-20%….should still be profitable…but it does allow scalability which is key to RENX being able to penetrate the addressable market. |
Posted at 09/4/2024 19:24 by f56 OK.I hear what you are saying. How do you think that would translate into profit for RENX if they have to follow that kind of model? |
Posted at 09/4/2024 16:26 by 1jat F56 - how relevant is the invitae case to RENX?I expect RENX has the IP/technology and will licence testing to labs….they certainly dont have the infrastructure to set up labs, lab cost will take a chunk of the $950 tariff for the test. |
Posted at 13/3/2024 14:28 by 1jat I am encouraged the founders/champions of RENX have bought into the fund raise…..but they are the funder of last resort at the moment.The fund raise provides an immediate stay of execution for the company and will allow the sale of business process to proceed without a gun to the directors heads….however they need to recognise that either they will need to sell the business or be prepared to fund the company until it can make itself cash generative. They must hope the continued adoption in clinical standards will result in substantial demand for tests. That is what gives me hope that they can land a decent offer and sell the company. |
Posted at 12/3/2024 09:53 by faz Good to see Howard Doran appointed as Business Manager to drive sales all of six months ago doesnt even list RENX as his employer. Fact he's yet another one in his mid 60s picking up a pension salary here probably means he's forgotten where he works. They know how to pick them |
Posted at 13/7/2023 12:11 by mikemine1 Correct me if I'm wrong but RENX has reached practically all it's milestones now except breakeven point. FDA was the last major hurdle even though that didn't stop the company gaining multiple insurance acceptances and recognition of the validity of it's product without it. It even has a link up with a huge sales outlet that should propel the revenue stream quicker than RENX could do themselves.It's all good to me and we only need to have a bit more patience to see what happens in the next 6 months. I also note the increased interest which has pushed the share price to the £1.40 mark from sub £1.00. Lots of reasons to be happy IMHO and lots of potential upside for the share price I reckon. |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
